Fig. 6.

In vivo antitumor activity of Oligo AS administered alone (A) or in combination with paclitaxel (B) in severe combined immunodeficient (SCID) mice bearing LNCaP xenografts and the protein expression profile of xenografts (C). (A) Oligo AS (10 or 25 mg/kg per day) or ASM (25 mg/kg per day) treatments were initiated on day 0 and given i.p., 5 days/week for 4 weeks. (B) Oligos were given i.p. at 25 mg/kg per day, 5 days/week for 4 weeks, and paclitaxel was given i.p. at 10 mg/kg per day, twice per week for 4 weeks. (C) The SCID mice bearing LNCaP xenografts (60–70 mg) were treated i.p. with Oligo AS (10 or 25 mg/kg) or ASM (25 mg/kg) for 7 consecutive days. Proteins from tumor homogenates were analyzed by Western blotting. The number under each band is expressed as a percentage of saline control, normalized by the corresponding β-actin level.